Ideaya Biosciences Inc Total Liabilities
Ideaya Biosciences Inc total liabilities. Based on the latest financial reports, Ideaya Biosciences Inc (IDYA) has total liabilities worth $110.79 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Ideaya Biosciences Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Ideaya Biosciences Inc (2017–2025)
Total liabilities of Ideaya Biosciences Inc from 2017 to 2025. This chart illustrates how Ideaya Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Ideaya Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Ideaya Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Ideaya Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
FIT Hon Teng Limited
F:0FJ
|
Germany | €3.18 Billion |
|
Infore Environment Technology Group Co Ltd
SHE:000967
|
China | CN¥18.81 Billion |
|
TechCreate Group Ltd.
NYSE MKT:TCGL
|
USA | $1.11 Million |
|
Clas Ohlson AB (publ)
ST:CLAS-B
|
Sweden | Skr5.06 Billion |
|
Magnite Inc
NASDAQ:MGNI
|
USA | $2.10 Billion |
|
Sigma Advanced Systems Limited
NSE:MEGASOFT
|
India | Rs242.03 Million |
|
Catcher Technology Co Ltd
TW:2474
|
Taiwan | NT$87.37 Billion |
|
China National Medicines Corp Ltd
SHG:600511
|
China | CN¥15.19 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Ideaya Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Ideaya Biosciences Inc total assets.
Liquidity & Leverage Metrics
Ideaya Biosciences Inc Total Liabilities Ratios Explained
Ideaya Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ideaya Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ideaya Biosciences Inc (2017–2025)
The table below shows the annual total liabilities of Ideaya Biosciences Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $86.39 Million | +33.02% |
| 2024-12-31 | $64.94 Million | +130.09% |
| 2023-12-31 | $28.23 Million | -26.71% |
| 2022-12-31 | $38.51 Million | -51.76% |
| 2021-12-31 | $79.83 Million | -20.16% |
| 2020-12-31 | $100.00 Million | +693.55% |
| 2019-12-31 | $12.60 Million | -91.34% |
| 2018-12-31 | $145.49 Million | +337.98% |
| 2017-12-31 | $33.22 Million | -- |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and … Read more